This Article  • References  • Full text PDF  • Send to a friend  • Save in My Folder  • Save to citation manager  • Permissions  Citing Articles  • Citation map  • Citing articles on HighWire  • Citing articles on Web of Science (8)  • Contact me when this article is cited  Related Content  • Similar articles in this journal  Social Bookmarking   What's this?

John A. Butler, MD; Thomas Trezona, MD; Hernan Vargas, MD; David State, MD

Arch Surg. 1989;124(10):1131-1135.

Abstract
• To assess the value of measuring the estrogen- and progesterone-receptor content of metastatic nodal disease, 38 women with node-positive breast cancer were prospectively evaluated. Receptor content of the primary tumor and a pathologically confirmed positive node were measured simultaneously using a dual-isotope, dextran-coated, charcoal-binding assay. A receptor content of greater than or equal to 10 fmol/mg of cytosol protein was considered positive for both the estrogen-receptor and progesterone-receptor assays. Overall concordance between the primary tumors and the nodal metastases was 82% (31/38 patients) for the estrogen-receptor measurements and 84% (31/37 patients) for the progesterone-receptor measurements. Paired receptor levels were significantly correlated: r =.745 for the estrogen-receptor measurements and r =.805 for the progesterone-receptor measurements. Despite this correlation, 6 (25%) of 24 patients with an estrogen receptor–positive primary tumor had an estrogen receptor–negative nodal metastasis. Four (20%) of 20 patients with a progesterone receptor–positive primary tumor had a progesterone receptor–negative nodal metastasis. Six (24%) of 25 patients with tumors labeled as hormonally sensitive on the basis of the receptor content of the primary tumor had receptor-negative nodal disease. In reflecting the hormonal status of the more aggressive elements of the primary tumor, receptor levels of metastatic nodes may provide more useful information than the levels of the primary tumor as a guideline for further therapy.

(Arch Surg. 1989;124:1131-1135)

Author Affiliations
From the Department of Surgery, Harbor-UCLA Medical Center.

Footnotes
Accepted for publication June 22, 1989.

Read before the 60th Annual Meeting of the Pacific Coast Surgical Association, Vancouver, Canada, February 22, 1989.

Reprint requests to the Department of Surgery, PO Box 25, Harbor-UCLA Medical Center, 1000 W Carson St, Torrance, CA 90502 (Dr Butler).

CiteULike    Connotea    Del.icio.us    Digg    Reddit    Technorati    Twitter     What's this?

THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES

Tanshinone I suppresses growth and invasion of human breast cancer cells, MDA-MB-231, through regulation of adhesion molecules
Nizamutdinova et al.
Carcinogenesis 2008;29:1885-1892.
ABSTRACT | FULL TEXT  

Estrogen Insensitivity in a Model of Estrogen Receptor Positive Breast Cancer Lymph Node Metastasis
Harrell et al.
Cancer Res. 2007;67:10582-10591.
ABSTRACT | FULL TEXT  

Estrogen receptor positive breast cancer metastasis: altered hormonal sensitivity and tumor aggressiveness in lymphatic vessels and lymph nodes.
Harrell et al.
Cancer Res. 2006;66:9308-9315.
ABSTRACT | FULL TEXT